Lysosomal Serine Protease CLN2 Regulates Tumor Necrosis Factor-α-mediated Apoptosis in a Bid-dependent Manner

Hélène Autefage, Virginie Albinet, Virginie Garcia, Hortense Bergès, Marie-Laure Nicolau, Marie-Françoise Altié, Catherine Caillaud, Thierry Levade, Nathalie Andrieu‐Abadie

Journal of Biological Chemistry · 2009 · 21 citations · 61 references

DOIFull text

Open access

Concepts

Abstract

Apoptosis is a highly organized, energy-dependent program by which multicellular organisms eliminate damaged, superfluous, and potentially harmful cells. Although caspases are the most prominent group of proteases involved in the apoptotic process, the role of lysosomes has only recently been unmasked. This study investigated the role of the lysosomal serine protease CLN2 in apoptosis. We report that cells isolated from patients affected with late infantile neuronal ceroid lipofuscinosis (LINCL) having a deficient activity of CLN2 are resistant to the toxic effect of death ligands such as tumor necrosis factor (TNF), CD95 ligand, or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not to receptor-independent stress agents. CLN2-deficient cells exhibited a defect in TNF-induced Bid cleavage, release of cytochrome c, and caspase-9 and -3 activation. Moreover, extracts from CLN2-overexpressing cells or a CLN2 recombinant protein were able to catalyze the in vitro cleavage of Bid. Noteworthy, correction of the lysosomal enzyme defect of LINCL fibroblasts using a medium enriched in CLN2 protein enabled restoration of TNF-induced Bid and caspase-3 processing and toxicity. Conversely, transfection of CLN2-corrected cells with small interfering RNA targeting Bid abrogated TNF-induced cell death. Altogether, our study demonstrates that genetic deletion of the lysosomal serine protease CLN2 and the subsequent loss of its catalytic function confer resistance to TNF in non-neuronal somatic cells, indicating that CLN2 plays a yet unsuspected role in TNF-induced cell death. Apoptosis is a highly organized, energy-dependent program by which multicellular organisms eliminate damaged, superfluous, and potentially harmful cells. Although caspases are the most prominent group of proteases involved in the apoptotic process, the role of lysosomes has only recently been unmasked. This study investigated the role of the lysosomal serine protease CLN2 in apoptosis. We report that cells isolated from patients affected with late infantile neuronal ceroid lipofuscinosis (LINCL) having a deficient activity of CLN2 are resistant to the toxic effect of death ligands such as tumor necrosis factor (TNF), CD95 ligand, or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not to receptor-independent stress agents. CLN2-deficient cells exhibited a defect in TNF-induced Bid cleavage, release of cytochrome c, and caspase-9 and -3 activation. Moreover, extracts from CLN2-overexpressing cells or a CLN2 recombinant protein were able to catalyze the in vitro cleavage of Bid. Noteworthy, correction of the lysosomal enzyme defect of LINCL fibroblasts using a medium enriched in CLN2 protein enabled restoration of TNF-induced Bid and caspase-3 processing and toxicity. Conversely, transfection of CLN2-corrected cells with small interfering RNA targeting Bid abrogated TNF-induced cell death. Altogether, our study demonstrates that genetic deletion of the lysosomal serine protease CLN2 and the subsequent loss of its catalytic function confer resistance to TNF in non-neuronal somatic cells, indicating that CLN2 plays a yet unsuspected role in TNF-induced cell death. Apoptosis is a highly organized, energy-dependent program by which multicellular organisms eliminate potentially harmful, superfluous, and damaged cells. Although caspases are the most prominent group of proteases involved in the apoptotic process, the role of lysosomes and more particularly of lysosomal cathepsins in cell death has only recently been unmasked (1.Leist M. Jaattela M. Cell Death Differ. 2001; 8: 324-326Crossref PubMed Scopus (183) Google Scholar, 2.Guicciardi M.E. Leist M. Gores G.J. Oncogene. 2004; 23: 2881-2890Crossref PubMed Scopus (637) Google Scholar, 3.Kroemer G. Jaattela M. Nat. Rev. Cancer. 2005; 5: 886-897Crossref PubMed Scopus (1078) Google Scholar, 4.Chwieralski C.E. Welte T. Buhling F. Apoptosis. 2006; 11: 143-149Crossref PubMed Scopus (334) Google Scholar, 5.Tardy C. Codogno P. Autefage H. Levade T. Andrieu-Abadie N. Biochim. Biophys. Acta. 2006; 1765: 101-125PubMed Google Scholar, 6.Stoka V. Turk V. Turk B. Biol. Chem. 2007; 388: 555-560Crossref PubMed Scopus (124) Google Scholar). Release of cathepsins from the lysosomal lumen to the cytosol is a prerequisite for their participation in the regulation of apoptosis and has been described in response to a variety of death stimuli such as inducers of cell-surface TNF 2The abbreviations used are: TNF, tumor necrosis factor-α; TNFR, TNF receptor; AAF-AMC, H-Ala-Ala-Phe amino methylcoumarin; AAF-cmk, H-Ala-Ala-Phe-fluoromethyl ketone; Ac-DEVD-AMC, Ac-Asp-Glu-Val-Asp-aminomethylcoumarin; CLN, ceroid lipofuscinosis; FCS, fetal calf serum; LINCL, late-infantile neuronal ceroid lipofuscinosis; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; AEBSF, 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; CHO, Chinese hamster ovary; PBS, phosphate-buffered saline; PMSF, phenylmethanesulfonyl fluoride; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; DMEM, Dulbecco's modified Eagle's medium; mAb, monoclonal antibody; siRNA, small interfering RNA. receptor family (7.Foghsgaard L. Wissing D. Mauch D. Lademann U. Bastholm L. Boes M. Elling F. Leist M. Jaattela M. J. Cell Biol. 2001; 153: 999-1010Crossref PubMed Scopus (567) Google Scholar, 8.Nilsson C. Johansson U. Johansson A.C. Kagedal K. Ollinger K. Apoptosis. 2006; 11: 1149-1159Crossref PubMed Scopus (84) Google Scholar, 9.Nagaraj N.S. Vigneswaran N. Zacharias W. Apoptosis. 2007; 12: 125-139Crossref PubMed Scopus (42) Google Scholar, 10.Werneburg N.W. Guicciardi M.E. Bronk S.F. Kaufmann S.H. Gores G.J. J. Biol. Chem. 2007; 282: 28960-28970Abstract Full Text Full Text PDF PubMed Scopus (112) Google Scholar), chemotherapeutic drugs (11.Emert-Sedlak L. Shangary S. Rabinovitz A. Miranda M.B. Delach S.M. Johnson D.E. Mol. Cancer Ther. 2005; 4: 733-742Crossref PubMed Scopus (91) Google Scholar, 12.Paris C. Bertoglio J. Breard J. Apoptosis. 2007; 12: 1257-1267Crossref PubMed Scopus (62) Google Scholar), or nonreceptor-mediated apoptotic agents (13.Brunk U.T. Svensson I. Redox Rep. 1999; 4: 3-11Crossref PubMed Scopus (161) Google Scholar, 14.Bivik C. Rosdahl I. Ollinger K. Carcinogenesis. 2007; 28: 537-544Crossref PubMed Scopus (104) Google Scholar). This lysosomal membrane permeabilization often relies on the activation of the intrinsic apoptosis pathway, which involves mitochondrial membrane permeabilization with the consequent release of the pro-apoptotic mitochondrial proteins into the cytosol. These factors lead to caspase activation and ultimately to cell death. In addition to the cathepsin-dependent pathway, some reports have indicated that other lysosomal proteins can modulate or mediate some cell death programs. Indeed, overexpression of CLN1/palmitoyl protein thioesterase 1 (15.Cho S. Dawson G. J. Neurochem. 2000; 74: 1478-1488Crossref PubMed Scopus (69) Google Scholar) or CLN3/battenin (16.Puranam K.L. Guo W.X. Qian W.H. Nikbakht K. Boustany R.M. Mol. Genet. Metab. 1999; 66: 294-308Crossref PubMed Scopus (90) Google Scholar) protected neuronal cells from stress-induced apoptosis. Moreover, we recently demonstrated that the apoptosis defect, reported in fibroblasts derived from patients affected with I-cell disease having a deficient activity of almost all lysosomal hydrolases (17.Terman A. Neuzil J. Kagedal K. Ollinger K. Brunk U.T. Exp. Cell Res. 2002; 274: 9-15Crossref PubMed Scopus (22) Google Scholar, 18.Tardy C. Autefage H. Garcia V. Levade T. Andrieu-Abadie N. J. Biol. Chem. 2004; 279: 52914-52923Abstract Full Text Full Text PDF PubMed Scopus (23) Google Scholar), could be partially corrected when the activity of CLN2/tripeptidyl peptidase 1 had been restored in these mutant cells (18.Tardy C. Autefage H. Garcia V. Levade T. Andrieu-Abadie N. J. Biol. Chem. 2004; 279: 52914-52923Abstract Full Text Full Text PDF PubMed Scopus (23) Google Scholar). However, how this lysosomal protease is connected with the apoptotic machinery has never been studied. The lysosomal serine protease CLN2 (EC 3.4.14.9) is the only hydrolase with tripeptidyl peptidase activity identified to date in the lysosomes of mammalian cells. This mannose 6-phosphorylated protease has an exopeptidase activity with an acidic pH optimum and cleaves off tripeptides sequentially from unsubstituted N termini of polypeptides or proteins. CLN2 also exhibits an endoprotease activity that may be important for the low pH-triggered intramolecular autoactivation of the inactive proenzyme to the mature form (19.Ezaki J. Takeda-Ezaki M. Oda K. Kominami E. Biochem. Biophys. Res. Commun. 2000; 268: 904-908Crossref PubMed Scopus (58) Google Scholar). Indeed, like caspases and cathepsins, CLN2 is synthesized as an inactive zymogen, and its activation involves proteolytic processing to yield a mature enzyme of 368 amino acid residues (∼48 kDa). Most mutations in the CLN2 gene lead to abolishment of the enzymatic activity and are the direct cause of a fatal childhood inherited neurodegenerative disease, the classical late-infantile form of neuronal ceroid lipofuscinosis (LINCL) (20.Sleat D.E. Donnelly R.J. Lackland H. Liu C.G. Sohar I. Pullarkat R.K. Lobel P. Science. 1997; 277: 1802-1805Crossref PubMed Scopus (513) Google Scholar, 21.Rawlings N.D. Barrett A.J. Biochim. Biophys. Acta. 1999; 1429: 496-500Crossref PubMed Scopus (93) Google Scholar, 22.Lin L. Sohar I. Lackland H. Lobel P. J. Biol. Chem. 2001; 276: 2249-2255Abstract Full Text Full Text PDF PubMed Scopus (115) Google Scholar). Although the structure of CLN2 has been recently studied (23.Liu C.G. Sleat D.E. Donnelly R.J. Lobel P. Genomics. 1998; 50: 206-212Crossref PubMed Scopus (60) Google Scholar, 24.Walus M. Kida E. 2005; PubMed Scopus (22) Google Scholar), its function and its reported that in CLN2 is able to such as G. Pullarkat R.K. J. Neurochem. 2000; 74: PubMed Scopus Google Scholar), D. Biochim. Biophys. Acta. 1998; PubMed Scopus Google Scholar), G. Pullarkat R.K. J. Neurochem. 2000; 74: PubMed Scopus Google Scholar), F. J. 2001; 5: Full Text PDF PubMed Scopus Google Scholar), and S. U. Biochem. Biophys. Res. Commun. 2004; PubMed Scopus Google Scholar), as as G. Pullarkat R.K. J. Neurochem. 2000; 74: PubMed Scopus Google Scholar), and Biochem. Biophys. Res. Commun. PubMed Scopus Google Scholar). The of has been also as a of the protease J. I. N. Kominami E. J. Neurochem. 1999; PubMed Scopus Google Scholar, J. Takeda-Ezaki M. Kominami E. J. Biochem. 2000; PubMed Scopus Google Scholar). However, this not only in LINCL but also in a of of neuronal ceroid lipofuscinosis and other lysosomal M. J. M. 1997; PubMed Scopus Google Scholar), that is to the yet role of CLN2 in we have used fibroblasts or isolated from patients affected with LINCL having a inactive but CLN2 The of mutant cells to apoptotic inducers with that of cells derived from as were the cell we that apoptosis by TNF as as ligands in CLN2-deficient cells as with cells a role of this serine protease in cell death. We also that the family pro-apoptotic Bid can be by recombinant TNF and were from from and CD95 ligand from the medium of cells that a CD95 ligand M. A. H. T. A. J. 1999; Google Scholar). recombinant CLN2 proenzyme by P. Lobel Bid and were from and from from DMEM, fetal calf and were from 4-(2-aminoethyl)-benzenesulfonyl fluoride and were from were from Cell fibroblasts derived from or from patients affected with LINCL were as described M. K. H. J. Levade T. Acta. 1997; PubMed Scopus Google Scholar). of fibroblasts were with a from J. the using of cell and mutant fibroblasts were to These cells were in a in and cell were from derived from or from patients affected with LINCL and were in medium this cells were with cells to and a L. Lobel P. Biochem. J. 2001; PubMed Scopus Google Scholar) or a mutant M. Kida E. 2005; PubMed Scopus (22) Google Scholar) form of CLN2 were by P. Lobel and A. The cell M. A. M. A. Mol. Genet. 2001; PubMed Google Scholar) a from A. and modified cells were in or cells were for in the medium of these cells and and to LINCL fibroblasts for in the or of with cell by using the F. J. PubMed Scopus Google Scholar), and the with TNF or and cells were and with phosphate-buffered Cell were in CHAPS, 1 1 PMSF, and of cell and of of the of the and for the and Release of with TNF and cells were and with Cell were in of 1 1 PMSF, and for on cells were by of a The for and were for of protein were by and by using 1 of proteins were in a and to a membrane were using an monoclonal monoclonal c, and were from Cell and used CLN2 by using a monoclonal by A. an used as a for protein activity using as reported M. Kida E. 2005; PubMed Scopus (22) Google Scholar). Cell were in of with and for of and of in with of the by of The of the by and for the and with the using as a fibroblasts were in for and with the cells were for 1 with a monoclonal and for 1 with with The with a monoclonal the of and with a with The were with and with a with a a were with and the of targeting this protein were into CLN2-corrected LINCL fibroblasts to using were used and in for TNF and were to the and cells were for to cell In Bid extracts from or cells were in with and of or not with 1 PMSF, 1 AEBSF, or for and of recombinant Bid of were by and by using an were by extracts by of CLN2 recombinant proenzyme that in or in with its with Bid. by on cells. were using and with were in the for with monoclonal used as a were on a are as The used for Death Cell a CLN2 the role of CLN2 in cell we used a genetic by fibroblasts and cell derived from patients affected with with fibroblasts or derived from the CLN2 enzymatic activity in all LINCL cells of the of the mutations reported in the CLN2 gene or In the of other lysosomal and in LINCL cells were not from in not Moreover, when of mutant cells were on using a the CLN2 the mature form most often the of a protein in these The of CLN2-deficient cells to death ligands this and LINCL fibroblasts were to TNF, CD95 ligand, or these stimuli are to apoptosis in the of demonstrates of these agents to a in the cell of fibroblasts all LINCL fibroblasts were more resistant to the of death ligands their The resistance of CLN2-deficient cells also on cell with an Altogether, these the of CLN2 in death to the of CLN2 in cell death by other and mutant fibroblasts were to the or to the protein which have been to apoptosis by the mitochondrial in and and LINCL cells were to the of these indicating that CLN2 not receptor-independent cells are not resistant to receptor-independent agents. and fibroblasts or cell were for or in medium with or Cell using the are of in not CLN2 in Death the of the lysosomal serine protease CLN2 in cell the apoptotic by TNF in fibroblasts cell by were in and LINCL cells Moreover, the of the proteins that form the apoptosis-inducing such as the and the not in CLN2-deficient cells caspase activity with the Ac-DEVD-AMC, which the cleavage in caspase-3 and we demonstrated that TNF-induced caspase processing in CLN2-deficient cells with these the activation of caspases in also abrogated in LINCL cells the role of CLN2 in we of apoptotic in TNF-induced activation not in CLN2-deficient However, of the pro-apoptotic protein Bid and release of cytochrome into the cytosol were in mutant cells. In the cleavage of caspase-9 and caspase-3 by the also in LINCL cells. Altogether, these the of CLN2 in the apoptotic by TNF with a of of of CLN2-deficient to TNF of of and the of apoptosis and the protein are to the of TNF by with the tumor necrosis factor factor Science. 1998; PubMed Scopus Google Scholar) or by the lysosomal membrane J. M. A. N. Lademann U. M. E. G. M. Jaattela M. J. Exp. 2004; PubMed Scopus Google Scholar), we the of these proteins affected by CLN2 in of and were in and CLN2-deficient cells. These that the resistance of the mutant cells is not of an of these proteins. of TNF-induced in CLN2-corrected LINCL that the resistance of LINCL fibroblasts to cell death of the loss of CLN2 catalytic we investigated the effect of CLN2 enzymatic correction of these mutant cells on their to this CLN2-deficient fibroblasts were with the medium of cells and a L. Lobel P. Biochem. J. 2001; PubMed Scopus Google Scholar) or a M. Kida E. 2005; PubMed Scopus (22) Google Scholar) form of In this the CLN2 is and to the of mutant fibroblasts mannose L. Lobel P. Biochem. J. 2001; PubMed Scopus Google Scholar). the lysosomal of CLN2 in corrected cells, we by the of CLN2 and a membrane CLN2 with an with The and were also in LINCL fibroblasts that were with a CLN2 not Moreover, as in when CLN2-deficient cells were for with the medium of cells the CLN2 the activity of this enzyme restored as with CLN2-deficient cells with the medium of cells or cells an inactive mutant form of CLN2 for the that CLN2-corrected mutant fibroblasts more to TNF-induced as with CLN2-deficient cells with the medium of cells or cells an inactive form of CLN2 This by caspase in the cleavage of in CLN2-corrected cells. These were by of caspase-3 processing Moreover, correction of the lysosomal enzymatic defect of CLN2 fibroblasts restored Bid cleavage, of the enzyme with the tripeptidyl AAF-cmk, a of CLN2 activity D. Biochim. Biophys. Acta. 1998; PubMed Scopus Google Scholar), this processing for caspase-3 transfection of CLN2-corrected cells with targeting which Bid protein by TNF Altogether, these that CLN2 plays a role in TNF apoptotic by Bid activation. In of Bid by proteolytic activation of Bid has been reported to a which lysosomal proteases could the mitochondrial membrane permeabilization V. Turk V. Turk B. Biol. Chem. 2007; 388: 555-560Crossref PubMed Scopus (124) Google Scholar). we that CLN2 of mitochondrial we the effect of extracts or a CLN2 recombinant protein on the cleavage of a recombinant Bid and we the by with caspase Bid for in of extracts from cells the CLN2 protein in the cleavage of Bid to that with by recombinant the cleavage of Bid when the with extracts derived from cells or cells the lysosomal protein thioesterase 1 as a of or other proteases Moreover, of extracts with almost Bid processing This cleavage also by the serine protease but not by which has been described to a serine protease in the processing of the CLN2 proenzyme to the mature form in Kida E. M. P. P. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus (60) Google Scholar). However, extracts the mature enzyme as in that the effect of CLN2-overexpressing cells on Bid by we a CLN2 recombinant protein from the medium of CLN2-overexpressing cells L. Lobel P. Biochem. J. 2001; PubMed Scopus Google Scholar) could Bid. this inactive proenzyme is to the mature form and activity 1 and acidic cleavage of Bid were with mature CLN2 This can be by and not pH to Bid cleavage to be in acidic CLN2 recombinant protein acidic pH and with Bid of Bid that cleavage these that the effect of CLN2 on Bid processing acidic In the has been that lysosomes an important role as in the apoptotic Indeed, stimuli were to or the lysosomal lysosomal permeabilization and the release of acidic proteases such or cathepsins into the cytosol. in the these lysosomal can to the of the apoptotic However, the by which lysosomes or cathepsins are involved in cell death are In this for the participation of the lysosomal serine protease CLN2 in cell death from CLN2-deficient cells were more resistant their to the of death correction of CLN2 enzyme activity in LINCL cells restored to The of CLN2 in apoptosis demonstrated by the that TNF-induced cleavage of release of mitochondrial cytochrome into the and the cleavage of caspase-9 and were all in CLN2-deficient cells. In cell death by the protein or the which are apoptosis inducers mitochondrial not in LINCL cells. Moreover, the of cell-surface and the which the apoptosis-inducing were not in CLN2-deficient cells that CLN2 of and the mitochondrial intrinsic apoptotic using cell in the CLN2 gene and a cell a inactive we that the catalytic function of CLN2 its proteolytic is a for TNF-induced cell death. the to be the which is to the mitochondrial of apoptosis in T. K. Turk V. R.M. Turk B. J. Biol. Chem. 2004; 279: Full Text Full Text PDF PubMed Scopus Google Scholar, M. J. M. C. V. S. M. W. A. A. S. Cell Death Differ. 2004; 11: PubMed Scopus Google Scholar, L. J. Biol. 2007; PubMed Scopus Google Scholar, G. L. A. S. U. V. Turk V. Turk B. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). cleavage of Bid in CLN2-deficient cells, correction of the lysosomal enzymatic defect restored Bid In TNF-induced cell death in CLN2-corrected LINCL cells having Bid indicating that the pro-apoptotic protein is for apoptosis. This is with that Bid plays an important role as the of lysosomal cathepsins in cytochrome cell death V. Turk B. T. D. H. M. D. S. Turk V. J. Biol. Chem. 2001; 276: Full Text Full Text PDF PubMed Scopus Google Scholar). The proteolytic activation of Bid can be by proteases as of cathepsins, and that Bid and has recently been reported that a from be involved in the regulation of apoptosis cleavage of Bid T. K. L. H. F. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). The that Bid could be by some other lysosomal also with the that in vitro of lysosomal extracts with V. Turk B. T. D. H. M. D. S. Turk V. J. Biol. Chem. 2001; 276: Full Text Full Text PDF PubMed Scopus Google Scholar), a of cathepsins, an of cathepsins and or P. B. D. Cell Death Differ. 2002; PubMed Scopus Google Scholar), a of the not of an Bid. This study demonstrates that Bid can be by an cleavage of Bid. the tripeptidyl peptidase CLN2 exhibits and exopeptidase be that other of Bid are by the reported to mediate apoptosis by on cleaves but also a activity J. Biochem. Cell Biol. 1997; PubMed Scopus Google Scholar). However, which of these is the apoptotic to be using Moreover, we that when in vitro the proteolytic activation of Bid by CLN2 an acidic such as of the activation of caspases S. J. Nat. Cell Biol. 2000; PubMed Scopus Google Scholar, E. J. 2001; PubMed Google Scholar), or of L. M. A. M. A. D. J. 2006; PubMed Scopus Google Scholar), are by has been that of cells with TNF in lysosomal membrane permeabilization that with an release of and cytosol C. Johansson U. Johansson A.C. Kagedal K. Ollinger K. Apoptosis. 2006; 11: 1149-1159Crossref PubMed Scopus (84) Google Scholar). In of cells with of the have been to of lysosomal cytosol lysosomal membrane and caspase activation A. E. M. F. M. C. M. P. L. A. S. Cancer Res. 2007; PubMed Scopus Google Scholar). with other lysosomal proteases that the lysosomal cell death (1.Leist M. Jaattela M. Cell Death Differ. 2001; 8: 324-326Crossref PubMed Scopus (183) Google Scholar, 2.Guicciardi M.E. Leist M. Gores G.J. Oncogene. 2004; 23: 2881-2890Crossref PubMed Scopus (637) Google Scholar, 3.Kroemer G. Jaattela M. Nat. Rev. Cancer. 2005; 5: 886-897Crossref PubMed Scopus (1078) Google Scholar), CLN2 be into the cytosol and Bid. with TNF, CLN2 from lysosomes to the as indicated by a by T. and N. to how CLN2 could with Bid the apoptotic is the of Bid to Indeed, has been reported that some of the family could form and the lysosomal membrane M. Brunk U.T. 2000; PubMed Scopus Google Scholar, M. Brunk U.T. 2001; PubMed Scopus Google Scholar) as in of fibroblasts with or with TNF, or Bid has been to to the lysosomal membrane to the release of K. Johansson A.C. Johansson U. G. K. N.S. Ollinger K. J. Exp. 2005; PubMed Scopus Google Scholar) or N. Guicciardi M.E. Gores G.J. J. 2004; PubMed Scopus Google Scholar, M.E. Bronk S.F. N.W. Gores G.J. 2005; Full Text Full Text PDF PubMed Scopus (69) Google Scholar), Moreover, to activation by or small interfering have that lysosomal membrane permeabilization is N.W. Guicciardi M.E. Bronk S.F. Kaufmann S.H. Gores G.J. J. Biol. Chem. 2007; 282: 28960-28970Abstract Full Text Full Text PDF PubMed Scopus (112) Google Scholar, N.W. Bronk S.F. Gores G.J. J. 2006; PubMed Scopus Google Scholar). Conversely, an has been reported to a effect by lysosomal M. Brunk U.T. 2000; PubMed Scopus Google Scholar, M. Brunk U.T. 2001; PubMed Scopus Google Scholar). these The of the to the of LINCL are other of ceroid of CLN2 in a loss and apoptosis were prominent in the of CLN2-deficient which to death of these I. Sleat D.E. M. Lobel P. J. Neurochem. 1999; PubMed Scopus Google Scholar). on the role of CLN2 in cell death may when the in vitro on CLN2-deficient cells by with the in are for some other lysosomal proteases that can apoptosis as described in P. M. W. K. L. H. A. B. M. K. C. J. PubMed Scopus Google Scholar, M. H. P. J. K. W. T. S. S. M. K. Kominami E. C. K. J. 2000; PubMed Google Scholar, H. J. M. T. Kominami E. K. C. K. P. J. 2001; PubMed Google Scholar, M. M. H. T. S. S. T. Kominami E. C. K. P. Mol. PubMed Scopus Google Scholar) or apoptosis in cells with stress agents P. C. Oncogene. 1998; PubMed Scopus Google Scholar, S. T. C. L. S. J. Exp. PubMed Scopus Google Scholar). However, is that the role by these to the or cell in processing and have been reported for in neuronal non-neuronal cells A. C. T. J. M. A. A. Cell Biol. 2007; 8: PubMed Scopus Google Scholar). This has also been for apoptotic such as the serine protease that as an protein in stress-induced neuronal cell death in to its role in other somatic cells Liu Biochem. Biophys. Res. Commun. 2007; PubMed Scopus Google Scholar). the that the neuronal loss that LINCL is not only to apoptosis be Indeed, that of the could mediate neuronal cell death in which neuronal ceroid in the of apoptosis 2007; PubMed Scopus Google Scholar). by for the the of CLN2 in death receptor apoptotic our to the that the lysosomal is an important of this cell death We M. J. for cell P. Lobel of and of for CLN2-overexpressing cells and recombinant CLN2 A. for in for cells to a mutant form of CLN2 and CLN2 monoclonal antibody; and A. and for cells.

References

61